Site 0104 - Dana Farber Cancer Institute — Boston, Massachusetts

Site 0104 - Dana Farber Cancer Institute is a clinical research site located in Boston, Massachusetts, United States 02215.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

Site 0104 - Dana Farber Cancer Institute has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Sponsors: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Site 0104 - Dana Farber Cancer Institute?

Site 0104 - Dana Farber Cancer Institute has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Site 0104 - Dana Farber Cancer Institute conducted?

Site 0104 - Dana Farber Cancer Institute has 1 clinical trials on record, with 1 currently active. Their work covers High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Is Site 0104 - Dana Farber Cancer Institute accredited by Crixeo Health?

Site 0104 - Dana Farber Cancer Institute has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Site 0104 - Dana Farber Cancer Institute?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.